PURPOSE: Enzastaurin is a selective inhibitor of protein kinase C beta. Prior phase I studies did not show increased drug exposures with escalating once daily administration. Limits from gastrointestinal absorption may be overcome by twice daily dosing, potentially improving antitumor effects. EXPERIMENTAL DESIGN: We conducted a phase I dose escalation study in 26 patients with recurrent malignant glioma, stratified by use of enzyme-inducing antiepileptic drugs, to investigate whether divided twice daily dosing results in higher exposures compared with once daily dosing. Phosphorylated glycogen synthase 3 beta was analyzed as a potential biomarker of enzastaurin activity. RESULTS: Enzastaurin was poorly tolerated at all dose levels evaluated (500, 800, and 1,000 mg total daily), with thrombocytopenia and prolonged QTc as dose-limiting toxicities. The average drug concentration of enzastaurin under steady-state conditions was doubled by twice daily dosing compared with daily dosing [1.990; 90% confidence interval (CI), 1.450-2.730]. Additionally, geometric mean ratios doubled with 800 versus 500 mg dosing for both daily (2.687; 90% CI, 1.232-5.860) and twice daily regimens (1.852; 90% CI, 0.799-4.292). Two patients achieved long-term benefit (over 150 weeks progression free). CONCLUSIONS: Higher and more frequent dosing of enzastaurin resulted in improved drug exposure but with unacceptable toxicity at the doses tested. Phosphorylated glycogen synthase 3 beta may be a useful biomarker of the biological activity of enzastaurin. Enzastaurin has activity in a subset of malignant glioma patients and warrants continued study in combination with other agents using a maximal once daily dose of 500 mg.
PURPOSE:Enzastaurin is a selective inhibitor of protein kinase C beta. Prior phase I studies did not show increased drug exposures with escalating once daily administration. Limits from gastrointestinal absorption may be overcome by twice daily dosing, potentially improving antitumor effects. EXPERIMENTAL DESIGN: We conducted a phase I dose escalation study in 26 patients with recurrent malignant glioma, stratified by use of enzyme-inducing antiepileptic drugs, to investigate whether divided twice daily dosing results in higher exposures compared with once daily dosing. Phosphorylated glycogen synthase 3 beta was analyzed as a potential biomarker of enzastaurin activity. RESULTS:Enzastaurin was poorly tolerated at all dose levels evaluated (500, 800, and 1,000 mg total daily), with thrombocytopenia and prolonged QTc as dose-limiting toxicities. The average drug concentration of enzastaurin under steady-state conditions was doubled by twice daily dosing compared with daily dosing [1.990; 90% confidence interval (CI), 1.450-2.730]. Additionally, geometric mean ratios doubled with 800 versus 500 mg dosing for both daily (2.687; 90% CI, 1.232-5.860) and twice daily regimens (1.852; 90% CI, 0.799-4.292). Two patients achieved long-term benefit (over 150 weeks progression free). CONCLUSIONS: Higher and more frequent dosing of enzastaurin resulted in improved drug exposure but with unacceptable toxicity at the doses tested. Phosphorylated glycogen synthase 3 beta may be a useful biomarker of the biological activity of enzastaurin. Enzastaurin has activity in a subset of malignant gliomapatients and warrants continued study in combination with other agents using a maximal once daily dose of 500 mg.
Authors: Margaret A Shipp; Ken N Ross; Pablo Tamayo; Andrew P Weng; Jeffery L Kutok; Ricardo C T Aguiar; Michelle Gaasenbeek; Michael Angelo; Michael Reich; Geraldine S Pinkus; Tane S Ray; Margaret A Koval; Kim W Last; Andrew Norton; T Andrew Lister; Jill Mesirov; Donna S Neuberg; Eric S Lander; Jon C Aster; Todd R Golub Journal: Nat Med Date: 2002-01 Impact factor: 53.440
Authors: Michael A Carducci; Luna Musib; Merrill S Kies; Roberto Pili; Mylene Truong; Julie R Brahmer; Patricia Cole; Rana Sullivan; Jeanne Riddle; Jill Schmidt; Nathan Enas; Vikram Sinha; Donald E Thornton; Roy S Herbst Journal: J Clin Oncol Date: 2006-09-01 Impact factor: 44.544
Authors: Svetlana Kotliarova; Sandra Pastorino; Lara C Kovell; Yuri Kotliarov; Hua Song; Wei Zhang; Rolanda Bailey; Dragan Maric; Jean Claude Zenklusen; Jeongwu Lee; Howard A Fine Journal: Cancer Res Date: 2008-08-15 Impact factor: 12.701
Authors: Wolfgang Wick; Michael Weller; Markus Weiler; Tracy Batchelor; Alfred W K Yung; Michael Platten Journal: Neuro Oncol Date: 2011-06 Impact factor: 12.300
Authors: Jiangbing Zhou; Kofi-Buaku Atsina; Benjamin T Himes; Garth W Strohbehn; W Mark Saltzman Journal: Cancer J Date: 2012 Jan-Feb Impact factor: 3.360
Authors: Peter P Ruvolo; Liran Zhou; Julie C Watt; Vivian R Ruvolo; Jared K Burks; Tilahun Jiffar; Steven Kornblau; Marina Konopleva; Michael Andreeff Journal: J Cell Biochem Date: 2011-06 Impact factor: 4.429
Authors: Erwin G Van Meir; Costas G Hadjipanayis; Andrew D Norden; Hui-Kuo Shu; Patrick Y Wen; Jeffrey J Olson Journal: CA Cancer J Clin Date: 2010 May-Jun Impact factor: 508.702
Authors: Ze-Yi Li; Cui Liang; Ming Ding; Xiang-Qin Weng; Yan Sheng; Jing Wu; Hao Lu; Xun Cai Journal: Am J Transl Res Date: 2020-12-15 Impact factor: 4.060
Authors: Lindsay B Kilburn; Mehmet Kocak; Rodney L Decker; Cynthia Wetmore; Murali Chintagumpala; Jack Su; Stewart Goldman; Anuradha Banerjee; Richard Gilbertson; Maryam Fouladi; Larry Kun; James M Boyett; Susan M Blaney Journal: Neuro Oncol Date: 2014-11-27 Impact factor: 12.300
Authors: E M Dunbar; B S Coats; A L Shroads; T Langaee; A Lew; J R Forder; J J Shuster; D A Wagner; P W Stacpoole Journal: Invest New Drugs Date: 2013-12-03 Impact factor: 3.850